| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA881: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies |
|
Medicine details |
|
| Medicine name | ripretinib (Qinlock®) |
| Formulation | 50 mg tablets |
| Reference number | 4260 |
| Indication | Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib |
| Company | Deciphera Pharmaceuticals, Inc |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/01/2022 |
| NICE guidance | TA881: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies |